MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Iovance Biotherapeutics EBITDA 2011-2026 | IOVA
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Iovance Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -390 M | -384 M | -449 M | -390 M | -340 M | -261 M | -206 M | -127 M | -91.9 M | -52.7 M | -26.9 M | -12 M | -22.6 M | -8.13 M | -21.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -8.13 M | -449 M | -185 M |
Quarterly EBITDA Iovance Biotherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -85.9 M | -110 M | -118 M | - | -79.3 M | -98.9 M | -115 M | - | -115 M | -107 M | -108 M | - | -97.9 M | -97.5 M | -89.9 M | - | -84.5 M | -81.1 M | -75.2 M | - | -58.1 M | -63.1 M | -70.6 M | - | -50.7 M | -49.6 M | -39.7 M | - | -34.4 M | -30.9 M | -26.6 M | - | -21.6 M | -23.1 M | -20.7 M | - | -18.3 M | -11.2 M | -6.74 M | - | -6.95 M | -6.02 M | -5.11 M | - | -2.78 M | -2.09 M | -2.24 M | - | -9.4 M | -1.03 M | -703 K | - | -1.62 M | -1.64 M | -3.13 M | - | -5.76 M | -10.5 M | -640 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -640 K | -118 M | -45.5 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
60.4 M | $ 3.13 | 0.16 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
901 M | $ 46.2 | 4.01 % | $ 12.5 B | USA |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
-69.8 M | $ 2.49 | 1.22 % | $ 69.5 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 6.85 | 1.93 % | $ 196 M | USA |
 |
Galectin Therapeutics
GALT
|
-20.1 M | $ 2.28 | 2.24 % | $ 146 M | USA |
 |
Galapagos NV
GLPG
|
-166 M | $ 28.82 | 1.51 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
595 M | $ 8.4 | 1.51 % | $ 6.83 B |  Spain |
 |
Genprex
GNPX
|
-21.2 M | $ 0.89 | 0.28 % | $ 830 K | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 94.21 | -1.35 % | $ 27.2 B | Germany |
 |
InflaRx N.V.
IFRX
|
-37.3 M | $ 2.37 | 20.05 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
-2.87 M | $ 0.82 | 3.97 % | $ 6.82 M |  Australia |
 |
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
-204 M | $ 76.34 | 1.45 % | $ 12.2 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-47.8 M | $ 1.49 | 3.83 % | $ 235 M | France |
 |
INmune Bio
INMB
|
-47.3 M | $ 1.51 | -1.95 % | $ 37.4 M | USA |
 |
Kamada Ltd.
KMDA
|
-696 K | $ 8.31 | 1.22 % | $ 260 M |  Israel |
 |
Kymera Therapeutics
KYMR
|
-341 M | $ 85.92 | 3.88 % | $ 7.26 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-7.74 M | $ 12.98 | -3.53 % | $ 1.72 B | Australia |
 |
ACADIA Pharmaceuticals
ACAD
|
232 M | $ 23.02 | 2.98 % | $ 3.81 B | USA |
 |
Liquidia Corporation
LQDA
|
-49.8 M | $ 41.73 | 3.97 % | $ 3.59 B | USA |
 |
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 3.56 | 1.71 % | $ 5.86 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
2.11 M | $ 106.77 | 0.9 % | $ 5.36 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | USA |
 |
MannKind Corporation
MNKD
|
51.1 M | $ 3.88 | 35.49 % | $ 1.19 B | USA |
 |
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
-20.9 M | $ 0.27 | -3.84 % | $ 660 M | Britain |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 23.63 | 0.9 % | $ 3.01 B | USA |
 |
Nanobiotix S.A.
NBTX
|
-52.6 M | $ 39.36 | 13.2 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | USA |